The SCCS Polypill Pilot Trial

Summary

In this study the investigators will examine the effect of the polypill on medication adherence, systolic blood pressure, and LDL cholesterol over a 12 month span.

Timeline

Start

2015-12

Primary completion

2018-06-27

Completion

2018-06-27

Outcome

Met primary endpoint

paper The mean systolic blood pressure decreased by 9 mm Hg in the polypill group, as compared with 2 mm Hg in the usual-care group PMID 31532959 ↗

paper difference, -7 mm Hg; 95% confidence interval [CI], -12 to -2; P = 0.003 PMID 31532959 ↗

paper LDL cholesterol level decreased by 15 mg per deciliter in the polypill group, as compared with 4 mg per deciliter in the usual-care group PMID 31532959 ↗

paper difference, -11 mg per deciliter; 95% CI, -18 to -5; P<0.001 PMID 31532959 ↗

Publications

• Munoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, Tousey P, Munro H, Gonzales H, Song W, White C, Blot WJ, Wang TJ. Polypill for Cardiovascular Disease Prevention in an Underserved Population. N Engl J Med. 2019 Sep 19;381(12):1114-1123. doi: 10.1056/NEJMoa1815359.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amlodipine	Other / unclassified	2.5 mg	—
Subject	Atorvastatin	Small molecule	10 mg	—
Subject	Hydrochlorothiazide	Unknown	12.5 mg	—
Subject	Losartan	Other / unclassified	25 mg	—

Indications